Psyence Biomedical Correlations
PBM Stock | USD 3.51 0.17 5.09% |
The current 90-days correlation between Psyence Biomedical and Tff Pharmaceuticals is 0.15 (i.e., Average diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Psyence Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Psyence Biomedical Ltd moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Psyence Biomedical Correlation With Market
Good diversification
The correlation between Psyence Biomedical Ltd and DJI is -0.01 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Psyence Biomedical Ltd and DJI in the same portfolio, assuming nothing else is changed.
Psyence |
Moving together with Psyence Stock
0.62 | LLY | Eli Lilly Sell-off Trend | PairCorr |
0.64 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.7 | RDY | Dr Reddys Laboratories | PairCorr |
0.65 | TAK | Takeda Pharmaceutical | PairCorr |
0.74 | INAB | In8bio Inc | PairCorr |
0.63 | INMB | INmune Bio | PairCorr |
0.62 | LTRN | Lantern Pharma | PairCorr |
0.79 | REVB | Revelation Biosciences | PairCorr |
0.76 | SIGA | SIGA Technologies | PairCorr |
Moving against Psyence Stock
0.79 | BHC | Bausch Health Companies | PairCorr |
0.74 | GILD | Gilead Sciences | PairCorr |
0.69 | EWTX | Edgewise Therapeutics | PairCorr |
0.64 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.54 | GANX | Gain Therapeutics | PairCorr |
0.53 | ESPR | Esperion Therapeutics | PairCorr |
0.42 | WAT | Waters | PairCorr |
0.72 | BSX | Boston Scientific Corp | PairCorr |
0.48 | SMMT | Summit Therapeutics PLC | PairCorr |
0.46 | ABT | Abbott Laboratories Fiscal Year End 22nd of January 2025 | PairCorr |
0.44 | CPRX | Catalyst Pharmaceuticals | PairCorr |
0.34 | MNMD | Mind Medicine | PairCorr |
Related Correlations Analysis
-0.05 | -0.75 | 0.07 | 0.85 | 0.44 | CUE | ||
-0.05 | 0.57 | 0.54 | 0.08 | -0.01 | TFFP | ||
-0.75 | 0.57 | 0.34 | -0.65 | -0.27 | ELYM | ||
0.07 | 0.54 | 0.34 | 0.14 | -0.16 | INBX | ||
0.85 | 0.08 | -0.65 | 0.14 | 0.16 | ELVN | ||
0.44 | -0.01 | -0.27 | -0.16 | 0.16 | MOLN | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Psyence Stock performing well and Psyence Biomedical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Psyence Biomedical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
CUE | 7.68 | 1.25 | 0.19 | 1.35 | 5.91 | 20.27 | 67.78 | |||
TFFP | 6.89 | (1.75) | 0.00 | (1.33) | 0.00 | 11.28 | 95.77 | |||
ELYM | 3.87 | (0.92) | 0.00 | (2.63) | 0.00 | 6.21 | 34.87 | |||
INBX | 2.30 | 0.11 | 0.02 | 0.27 | 2.70 | 5.54 | 16.80 | |||
ELVN | 1.96 | 0.09 | 0.04 | 0.20 | 2.06 | 5.84 | 12.96 | |||
MOLN | 4.53 | (0.20) | 0.00 | (0.02) | 0.00 | 9.38 | 52.92 |
Psyence Biomedical Corporate Management
Taryn Vos | General Counsel | Profile | |
Tony Budden | Chief Officer | Profile | |
MaryElizabeth Gifford | Executive Impact | Profile | |
Warwick CordenLloyd | Chief Officer | Profile |